Could this new vaccine stop shingles for years?
NCT ID NCT07293065
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This Phase 3 trial is testing a new shingles vaccine in 12,000 adults aged 40 and older. The goal is to see if the vaccine can prevent shingles for up to 3 years after the two-dose series. Participants previously received the vaccine or a placebo, and researchers are tracking who develops shingles over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hebei Provincial Center for Disease Control and Prevention
Shijiazhuang, Hebei, 050021, China
-
Henan Center for Diseases Control and Prevention
Zhengzhou, Henan, 450016, China
-
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, 430070, China
-
Yunnan Center For Disease Control and Prevention
Kunming, Yunnan, 650022, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant Zoster Vaccine (CHO Cell) with adjuvant
What this could lead to
If successful, this vaccine could provide long-term protection against shingles for adults 40 and older, reducing pain and complications.
What could go wrong
This is a large Phase 3 trial, but results are not yet available. The vaccine may not prove effective over the full 3 years, and side effects like injection-site reactions are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.